1820. In Vitro Global Surveillance of Eravacycline and Comparators against Staphylococcus spp. and Enterococcus spp. Over a Three-year Period (2013-15)
Session: Poster Abstract Session: Antibacterial Susceptibility Surveillance
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • 1820_FINAL.pdf (270.9 kB)
  • Background: Eravacycline (ERV) is a novel, fully-synthetic fluorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. As methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE) have been designated as serious public threats by the CDC, the purpose of this study was to evaluate the activity of ERV and comparators against global isolates of Staphylococcus spp. and Enterococcus spp. collected from 2013-15.

    Methods: Clinical isolates were collected from various body sites in patients in hospitals worldwide from 2013-15. MIC results for ERV and comparators were determined by CLSI broth microdilution.

    Results: ERV and comparator MIC results are shown in the table below. MIC90 values for the organisms did not vary more than one dilution over the 3-year time range.

    Organism

    ERV

    TGC

    VAN

    N

    MIC50/90

    MIC Range

    N

    MIC50/90

    MIC Range

    N

    MIC50/90

    MIC Range

    Enterococcus faecalis

    919

    0.06/0.06

    0.008-0.5

    919

    0.12/0.25

    ≤ 0.015-8

    915

     1/2

    0.12->32

    VR E. faecalis

    35

    0.06/0.12

    0.03/0.25

    35

    0.12/0.25

    0.06-0.5

    35

    >32/>32

    >16->32

    Enterococcus faecium

    696

    0.03/0.06

    0.008-1

    696

    0.12/0.12

    0.03-8

    694

    1/>32

    ≤ 0.12->32

     VR E.faecium

    310

    0.06/0.06

    0.008-1

    310

    0.12/0.25

    0.03-4

    310

    >32/>32

    >16->32

    Staphylococcus aureus

    1512

    0.06/0.12

    ≤ 0.008-1

    1512

    0.12/0.25

    0.03-1

    532

    1/1

    ≤ 0.25-2

    MRSA

    756

    0.06/0.12

    0.015-1

    756

    0.12/0.25

    0.03-1

    263

    1/1

    <=0.25-2

    Staphylococcus epidermidis

    483

    0.12/0.5

    ≤ 0.008-1

    483

    0.25/0.5

    ≤ 0.015-1

    206

    2/2

    0.5-2

    Staphylococcus haemolyticus

    305

    0.12/0.5

    0.015-2

    305

    0.25/0.5

    0.03-1

    148

    2/2

    0.5-4

    MIC50/90, minimum inhibitory concentration required to inhibit growth of 50/90% of isolates (mg/L); VR, vancomycin-resistant; MRSA, methicillin-resistant S. aureus

    Conclusion: Eravacycline demonstrated consistent and potent in vitro activity against a global collection of Staphylococcus spp. and Enterococcus spp., including resistant strains, over a recent 3-year time period (2013-2015). The in vitro potency for ERV against these organisms was up to 4-fold greater than TGC and a minimum of 8– fold greater than VAN.

    Matteo Bassetti, MD, PhD1, Ralph Corey, MD2, Yohei Doi, MD, PhD3, Ian Morrissey, PhD4, Trudy Grossman, PhD5, Melanie Olesky, PhD6, Patrick Scoble, PharmD7 and Joyce Sutcliffe, PhD6, (1)San Martino Hospital, Genova, Italy, (2)Duke University Medical Center, Durham, NC, (3)Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, (4)IHMA Europe Sàrl, Epalinges, Switzerland, (5)Tetraphase Pharmaceuticals, Watertown, MA, (6)Tetraphase Pharmaceuticals, Inc., Watertown, MA, (7)Former Employee Tetraphase Pharmaceuticals, Watertown, MA

    Disclosures:

    M. Bassetti, None

    R. Corey, None

    Y. Doi, None

    I. Morrissey, IHMA: Employee , Salary

    T. Grossman, Tetraphase Pharmaceuticals: Employee , Salary

    M. Olesky, Tetraphase Pharmaceuticals: Employee , Salary

    P. Scoble, Tetraphase Pharmaceuticals: Employee , Salary

    J. Sutcliffe, Tetraphase Pharmaceuticals: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.